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Background: The goal of the study is to investigate the association between the APOA5 polymorphisms and
haplotypes with Arterial Hypertension (AHT) in Moroccan patients.
Methods: The study was performed in 283 subjects, 149 patients with AHT and 134 controls. All subjects were
genotyped for the APOA5 -1131 T > C (rs662799), 56C > G (rs3135506) and c.553G > T (rs2075291) polymorphisms.
Results: There was a strong association between −1131 T > C and 56C > G polymorphisms with AHT. The -1131
T > C and 56C > G polymorphisms were significantly associated with increased systolic blood pressure (SBP) and
triglycerides (TG) levels. There were 4 haplotypes with a frequency higher than 5%, constructed from APOA5
polymorphisms, with the following order: −1131 T > C, 56C > G and c.553G > T. Haplotype H1 (TCG) was associated
with decreased risk of AHT, whereas the haplotypes H2 (CCG) and H4 (CGG) were significantly associated with an
increased risk of AHT. Carriers of H1 haplotype had a lower SBP and DBP and TG. In contrast, significant elevated
SBP, DBP and TG were found in H4 haplotypes carriers.
Conclusions: Our data demonstrate for the first time that several common SNPs in the APOA5 gene and their
haplotypes are closely associated with modifications of blood pressure and serum lipid parameters in the
AHT patient.
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Arterial hypertension (AHT) is one of major public health
problem in the world, it will affect more than 1.56 billion
adults worldwide in 2025 [1]. Hypertensive individuals
have higher risk to develop coronary artery disease
(CAD), cerebrovascular disease and heart failure than
normotensive persons [2]. Effectively, The American
Heart Association reported that the hypertension and
dyslipidemia are one of the main risk factor for devel-
opment of CAD [3,4]. AHT is a polygenic and multifac-
torial disease resulting from combination between
genetics and environment factors.* Correspondence: hamid.barakat@pasteur.ma
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unless otherwise stated.Apolipoprotein A5 (APOA5) gene, related to the me-
tabolism of triglycerides in several different ethnic
groups [5]. It locates on chromosome 11q23, and forms
a cluster with APOA4, APOC3 and APOA1 genes. In
mice, invalidation and over-expression of APOA5 result
in increased and decreased triglyceride levels, respect-
ively by controlling the activity of lipoprotein lipase
(LPL) [1]. APOA5 codes for a protein of 366 amino acids
which function is to modulate intracellular hepatic
VLDL synthesis. The most studied APOA5 SNP was the
56C > G (S19W, rs 3135506), because it is associated
with increased TG levels [6,7]. Indeed, numerous studies
in different ethnic populations have shown significant
associations between two minor APOA5 haplotypes,
APOA5*2 and APOA5*3, and elevated plasma triglycer-
ide levels [5,8]. It is estimated that 53% of Hispanics,
35% of African-Americans, and 24% of Caucasians carryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that these haplotypes are common risk factors for
atherosclerosis.
In this study, we investigated the association of the




Our study concerned 283 Moroccan adult volunteers (177
women and 106 men), 149 patients diagnosed as hyperten-
sive by medical corps (systolic blood pressure >140 mmHg
and/or diastolic blood pressure >90 mmHg, and treated by
antihypertensive drugs) and 134 controls (non smoking
healthy persons with normal lipid levels and normal blood
pressure, and women were non-pregnant and non-breast-
feeding). At enrolment in the Medical Biology Center of
Pasteur Institute of Morocco in Casablanca, they com-
pleted a health and lifestyle questionnaire including social
demographics characteristics, medical history, medications
intake and lifestyle factors as tobacco consumption, phys-
ical activity and alcohol intake. The clinical examination
consisted of questionnaire and a physical examination:
age, gender, geographical origin, family history, body mass
index, smoking habits, the presence of hypertension, dia-
betes, hypercholesterolemia or cocaine use, and levels
of physical activity and alcohol consumption per-
formed at the Pasteur Institute in Casablanca. All sub-
jects (patients and controls groups) included in this
study were from different geographic and ethnic back-
grounds from Morocco.
Ethics statement
We obtained written informed consent from each subject
and the research protocol was approved by the committee
on research ethics of Pasteur Institute of Morocco.
Blood pressure measurement
Arterial pressure was measured by the auscultatory
method using a stethoscope and a sphygmomanometer.
All measurements were performed by nurse in the Med-
ical Biology Center of Pasteur Institute of Morocco in
Casablanca.
Biochemical measurements
The blood was collected in two tubes (EDTA and dry
tubes) from subject after 12 hours overnight fasting. The
samples were centrifuged and stored at −20°C. Glycemia,
total cholesterol (TC), Triglycerides (TG) and High-
Density Lipoprotein Cholesterol (HDL-C) levels were
determined using the VITROS (5.1 FS Chemistery
System). Low-density Lipoprotein Cholesterol (LDL-C)
level was calculated according to the Friedwald’s for-
mula. All biochemical measurements were performed inthe Biochemistry Laboratory of the Medical Biology
Center in Pasteur Institute of Morocco.
Molecular analysis: genotyping APOA5 polymorphisms
Genomic DNA was extracted from peripheral leukocytes
by standard methods including proteinase K digestion,
followed by phenol–chloroform extraction and ethanol
precipitation. The 56C > G and −1131 T > C polymor-
phisms were determined by PCR-RFLP analysis. All PCR
were performed in a Biometra thermal cycler, using Taq
Polymerase (Bioline). A fragment of 157 bp including
the 56C > G polymorphism was amplified using two
oligonucleotides, forward: 5′- GGC TCT TCT TTC
AGG TGG GTCBTCCG -3′reverse: 5′- GCC TTT CCG
TGC CTG GGT GGT -3′ [9]. The PCR conditions were
an initial denaturing at 96°C for 5 min, followed by 30 cy-
cles of 96°C for 30 s, 64°C for 30 s, 72°C for 45 s, and a
final extension of 72°C for 10 min. The PCR products
were digested for 2 hours at 65°C with TaqI restriction
enzyme: the C56 allele presents a TaqI restriction site
which is suppressed in the 56G allele. Genotyping
for −1131 T >C was performed with the following primers:
Forward: 5′- CCC CAG GAA CTG GAG CGA AA
TT-3′, reverse 5′- TTC AAG CAG AGG GAA GCC
TGTA-3′. The PCR conditions were an initial denaturing
at 96°C for 5 min, followed by 32 cycles of 95°C for 30 s,
55°C for 30 s, 72°C for 30 s, and a final extension of 72°C
for 10 min. The PCR products were digested with Mse I.
A fragment of 138 bp of the c.553G > T polymorphism
was amplified using two oligonucleotides. The PCR condi-
tions were an initial denaturing at 96°C for 5 min,
followed by 35 cycles of 96°C for 30 s, 63°C for 30 s, 72°C
for 45 s, and a final extension of 72°C for 10 min. The
PCR products were digested for overnight at 37°C with
HaeIII restriction enzyme. All molecular analyses were
performed in the Human Genetic Laboratory in Pasteur
Institute of Morocco.
Statistical analysis
Clinical and biochemical data were expressed as means ±
standard deviation (SD). Student’s t test was applied for
comparison of quantitative traits that follow a normal
distribution. Otherwise, we used Manne-Whitney test.
Chi-square test and logistic regression analysis were per-
formed to test the association between Arterial Hyperten-
sion and APOA5 genotypes and haplotypes. Logistic
regression analysis was adjusted by age and gender. A P
value of less than 0.05 was considered statistically signifi-
cant. All statistical analyses were performed using STATA
software, version 11.0. The P-values were corrected with
the Bonferroni correction by multiplying with the number
of comparisons. For haplotype frequencies estimation and
comparison we used the PLINK software, version 1.07. All
haplotypes with frequencies less than 5% were ignored in
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APOA5 polymorphisms was estimated using Haploview
software, version 4.2.
Results
Characteristics of controls and patients
Clinical characteristics and lipid parameters of AHT pa-
tients and controls are presented in Table 1. As ex-
pected, age, triglyceridemia (TG), LDL, total cholesterol
(TC), Glycemia (Gly), CT/HDL ratio, Sbp and Dbp were
significantly different between AHT patients and con-
trols. In addition, HDL/LDL ratio was significantly ele-
vated in controls. There was no significant difference in
body mass index (BMI) and HDL between both groups.
Genotype frequency and linkage disequilibrium
The −1131 T > C, 56C > G SNPs had a strong association
with AHT in all genetic models, the p-values remained
significant after Bonferroni correction. The c.553G > T
polymorphism had a significant association with AHT in
co-dominant and dominant models, but this association
was lost after Bonferroni correction (Table 2).
To determine the extent of linkage disequilibrium (LD)
among the three polymorphisms, standardized LD coeffi-
cient D’ was calculated for all pairs of polymorphisms.
Figure 1 shows that with the exception of −1131 T > C
and 56C >G polymorphisms which were in strong linkage
disequilibrium (D’ = 50), other polymorphisms were not in
linkage disequilibrium (Figure 1).
Comparisons of clinical and biochemical parameters
between APOA5 genotypes
We compared biological and clinical traits between
APOA5 genotypes under dominant model for all patientsTable 1 Clinical and biochemical characteristics of
controls and patients with AHT
Controls (n = 134) Patients (n = 149) P-value
Age (years) 50.78 ± 12.08 59.76 ± 11.65 <0.0001
Sbp (mmgHg) 121.69 ± 6.77 153.09 ± 19.19 <0.0001
Dbp (mmgHg) 77.49 ± 7.97 85.97 ± 10.91 <0.0001
BMI (kg/m2) 26.49 ± 4.11 27.42 ± 4.63 0.0739
TG (g/L) 0.98 ± 0.31 1.65 ± 0.85 <0.0001
LDL (g/L) 1.15 ± 0.28 1.34 ± 0.45 <0.0001
HDL (g/L) 0.51 ± 0.13 0.50 ± 0.17 0.5042
Gly (g/L) 0.91 ± 0.14 1.23 ± 0.57 <0.0001
TC (g/L) 1.88 ± 0.28 2.12 ± 0.51 <0.0001
TC/HDL 3.90 ± 0.94 4.64 ± 1.61 <0.0001
HDL/LDL 0.48 ± 0.24 0.43 ± 0.32 0.0002
BMI: bodymass index, TC: Serum total cholesterol, TG: Triglycerides,
HDL: High-Density Lipoprotein Cholesterol, LDL: Low-density Lipoprotein
Cholesterol, Sbp systolic blood pressure, Dbp diastolic blood pressure.and controls combined. The APOA5 -1131 T > C
polymorphism was significantly associated with in-
creased levels of systolic blood pressure, diastolic blood
pressure and triglycerides (all P values <0.0001). We
found significantly elevated systolic blood pressure
(P = 0.0001) and triglycerides levels (P < 0.0001) in associ-
ation with APOA5 56C >G polymorphism. No Significant
association was observed for APOA5 c.553G > T poly-
morphism (Table 3).
APOA5 haplotype analysis
To examine the combined effect of three variants (in the
order of − 1131 T > C, 56C > G and c.553G > T polymor-
phisms of APOA5) in the APOA5 gene. There were 4
haplotypes identified in the APOA5gene in our popula-
tion, with frequencies greater than 5% (Table 4). Results
of the logistic regression analysis suggested that the
haplotype H1 (APOA5*1) has a protective effect against
AHT. Two haplotypes confers significant susceptibility
to AHT; haplotype H2 (APOA5*2) and haplotype H4.
No significant association was observed between the
haplotype H3 (APOA*3) and AHT. The frequencies of
the four haplotypes are listed in Table 4. Analysis of
the interaction between haplotypes, Serum lipid parame-
ters and environment factors showed that the H1 haplo-
type was associated with lower systolic blood pressure
(SBP), diastolic blood pressure (DBP) and total plasma
(TG). The H2 haplotype was significantly associated with
increased SBP. Carriers of the H4 haplotype had a sig-
nificant increased SBP, DBP and TG. No significant
difference was detected between carriers and non-
carriers of H3 haplotype. Age, BMI, LDL, HDL and gly-
cemia were also analyzed but no significant difference
was found in these parameters among the four haplo-
types (Table 5).
Discussion
Many evidences were reported showing that apolipopro-
tein A1/C3/A4/A5 gene cluster is associated with pre-
mature coronary artery disease [10] and serum lipid
levels [10]. Recent findings indicate that APOA5 could
also influence cholesterol homeostasis and probably
could play a role in hypertriglyceridemia associated with
diabetes and inflammation [11].
The APOA5 polymorphisms were also identified to
be implicated in regulation of blood pressure and in
the development of hypertension in Japanese popula-
tion [12].
Our data demonstrate that the 56C > G SNP has a
significant influence on blood pressure and triglyceride
levels. This variant had not previously been investi-
gated in Moroccan populations, although several
different studies of other populations are available,
supporting the importance of our study. The frequency
Table 2 Genotypic distribution of APOA5 polymorphisms and statistic comparison between AHT subjects and controls
SNP Model Controls Patients OR (95% CI) P Pc
−1131 T > C
Codominant
TT 128 (95.5%) 97 (65.1%) 1.00
TC 2 (1.5%) 20 (13.4%) 11.16 (2.46-50.69) 0.002 0.006*
CC 4 (3%) 32 (21.5%) 14.20 (4.50-44.77) <0.0001 <0.0001*
Dominant
TT 128 (95.5%) 97 (65.1%) 1.00
TC/CC 6 (4.5%) 52 (34.9%) 13.20 (5.14-33.91) <0.0001 <0.0001*
Recessive
TT/TC 130 (97%) 117 (78.5%) 1.00
CC 4 (3%) 32 (21.5%) 12.35 (3.91-39.05) <0.0001 <0.0001*
56C > G
Codominant
CC 117 (87.3%) 106 (71.1%) 1.00
CG 15 (11.2%) 21 (14.1%) 1.54 (0.72-3.29) 0.269 NS
GG 2 (1.5%) 22 (14.8%) 13.75 (3.01-62.75) 0.001 0.003*
Dominant
CC 117 (87.3%) 106 (71.1%) 1.00
CG/GG 17 (12.7%) 43 (28.9%) 2.90 (1.49-5.63) 0.002 0.006*
Recessive
CC/CG 132 (98.5%) 127 (85.2%) 1.00
GG 2 (1.5%) 22 (14.8%) 12.77 (2.82-57.73) 0.001 0.003*
c.553G > T
Codominant
GG 130 (97%) 132 (88.6%) 1.00
GT 3 (2.2%) 15 (10.1%) 4.72 (1.28-17.35) 0.020 NS
TT 1 (0.8%) 2 (1.3%) 1.64 (0.14-19.78) 0.695 NS
Dominant
GG 130 (97%) 132 (88.6%) 1.00
GT/TT 4 (3%) 17 (11.4%) 3.92 (1.23-12.43) 0.02 NS
Recessive
GG/GT 133 (99.2%) 147 (98.7%) 1.00
TT 1 (0.8%) 2 (1.3%) 1.47 (0.12-17.70) 0.763 NS
NS: Not Significant.
Pc: P value corrected for multiple comparisons (Bonferroni correction).
*P values remains significant after Bonferroni correction.
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(22%) is higher than that of European populations.
Indeed, studies carried out with North Americans
and Europeans found that the 56G allele frequency is
around 6% [6,7,13], whereas its frequency in North
Americans of Hispanic ancestry is around 15% [14].
Ruiz- Narváez registered a value of 10.2% for the
56G allele in Costa Rica, while other populations
exhibited lower frequencies in the same study (Caucasians6%, African-Americans 7%) [15]. In addition to these
studies, in 2003, Lai et al. investigated the frequency
of the same polymorphism in people resident in
Singapore [8]. The Chinese, Malay and Indian popula-
tions living in this region exhibited extremely low
frequencies of the 56G polymorphism (0.1%, 1% and
3%, respectively). The 56G allele frequency varies be-
tween 0.1% in a Chinese population [8] and 15.8% in
Hispanic males [16].
Figure 1 The linkage disequilibrium (LD) between the three
APOA5 SNPs.
Table 3 Association between APOA5 genotype variants and c
APOA5 -1131 T > C APOA5 56C
TT TC + CC P-value CC
Patient (number) 97 52 106
Controls (number) 128 6 117
Age (years) 54.94 ± 12.62 57.72 ± 12.68 0.1353 55.13 ± 12.6
Sbp (mmgHg) 133.67 ± 19.71 155.86 ± 18.94 <0.0001** 135.32 ± 20.
Dbp (mmgHg) 80.57 ± 10.60 87.33 ± 8.24 <0.0001** 81.27 ± 9.43
BMI (kg/m2) 26.82 ± 4.21 27.58 ± 5.11 0.2428 26.79 ± 4.21
TG (g/L) 1.23 ± 0.63 1.76 ± 0.93 <0.0001** 1.23 ± 0.64
LDL (g/L) 1.22 ± 0.37 1.37 ± 0.44 0.0101* 1.24 ± 0.38
HDL (g/L) 0.51 ± 0.17 0.47 ± 0.11 0.0631 0.51 ± 0.16
Gly (g/L) 1.06 ± 0.46 1.13 ± 0.43 0.0582 1.09 ± 0.48
TC (g/L) 1.97 ± 0.41 2.15 ± 0.52 0.0045* 1.98 ± 0.41
*P values not significant after Bonferroni correction.
**P values remains significant after Bonferroni correction.
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the regulation of LPL activity [17,18]. ApoAV protein
could facilitate the interaction between TG rich lipopro-
teins and proteoglycan-bound LPL. Transgenic mice
models also suggested that apoAV might inhibit VLDL
hepatic production but these findings were not con-
firmed in lipoprotein kinetic studies [19].
Although the association of 56C > G polymorphism
with lipid profile was already shown in various healthy
populations [20], their impact on AHT dyslipidemia re-
mains undocumented. In another study, this poly-
morphism was associated with higher TG and lower
HDLc in diabetic patients, but only for Indian-Asian
carriers [21]. There was no report of the impact of
this polymorphism on history of dyslipidemia in
AHT. Nevertheless, an increased 56G allele frequency
was previously reported in non diabetic patients with
severe hypertriglyceridemia [22,23]. The association
between the 56G allele and increased triglycerides
has already been documented in other populations,
such as the North American and Northern Irish popu-
lations [24,25]. The results of the present study confirm
the relationship between APOA556C > G polymorphism
and plasma triglycerides, as carriers of the 56G variant
were associated strongly with triglyceride levels. In
addition to elevated triglyceride levels, the APOA5 56G
was associated with higher systolic blood pressure rela-
tive to 56C carriers. A direct effect of APOA5 on blood
pressure regulation is unlikely. In contrast, there is ex-
perimental evidence to suggest that chronic hypertri-
glyceridemia leads to endothelium dysfunction, which
is associated with an impaired response to vasodilator
stimulation [26] and a subsequent decrease in nitriclinical and biochemical parameters
> G APOA5 c.553G > T
CG + GG P-value GG GT + TT P-value
43 132 17
17 130 4
2 56.90 ± 12.82 0.3386 55.24 ± 12.84 58.81 ± 9.87 0.215
27 148.98 ± 22.62 0.0001** 137.82 ± 21.15 143.24 ± 25.40 0.2495
84.48 ± 13.59 0.0355* 82.13 ± 10.33 79.81 ± 12.60 0.3319
27.68 ± 5.06 0.1676 27.09 ± 4.41 25.63 ± 4.30 0.1446
1.75 ± 0.91 <0.0001** 1.32 ± 0.74 1.53 ± 0.65 0.0564
1.31 ± 0.43 0.1889 1.25 ± 0.39 1.30 ± 0.43 0.5751
0.47 ± 0.12 0.0746 0.50 ± 0.16 0.53 ± 0.16 0.3976
1.04 ± 0.29 0.9913 1.06 ± 0.43 1.33 ± 0.65 0.0668
2.10 ± 0.51 0.0627 2.00 ± 0.44 2.13 ± 0.42 0.1688
Table 4 Association analysis of haplotypes derived from polymorphic sites using genotype data
Haplotype −1131 T > C 56C > G c.553G > T Frequency OR (95% CI) P Pc
Controls Cases
H1 T C G 0.8970 0.6543 0.338 (0.226-0.504) <0.0001 <0.0001
H2 C C G 0.0307 0.1307 3.07 (1.49-6.31) 0.0005 0.002
H3 T G G 0.0649 0.0625 0.809 (0.395-1.66) 0.563 NS
H4 C G G 0.0073 0.1525 12.46 (2.93-53 ) <0.0001 <0.0001
NS: Not Significant.
Pc: P value corrected for multiple comparisons (Bonferroni correction).
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creased blood pressure.
We found a significant difference between patients with
AHT and controls regarding the frequency of 56C > G
and -1131 T > C genotypes in the additive, dominant
and recessive models.
Several studies demonstrated that the presence of
polymorphisms in the A1-C3-A4 cluster and other
gene loci determines the variability of the postprandial
lipoprotein response [27,28]. Recently a gene coding
for APOA5 was identified in this cluster, and this is
emerging as a main candidate gene for modulating
TG metabolism in humans [6]. Two polymorphisms,-
1131 T > C and 56C > G, have been extensively studied
and are independently associated with higher TG levels
[6,28,29]. Previous studies have shown that plasma TG
concentrations were 69% higher in CC subjects than
TT subjects with the-1131 T > C polymorphism [8,30]
and 20–30% higher in CG than CC subjects with the
56C > G polymorphism [6,31]. Moreno et al. demon-
strated that carriers of the -1131C allele (−1131 T > C)
displayed a higher plasma TG concentration [32]. How-
ever, association studies using haplotypes should increase
our ability to detect true associations and interactions.
The ApoA5 -1131C allele in our study population was
similar to that in Chinese (29.9%) [33-35], Singaporean
(29.4%) [8], Malays (30.0%) [8], slightly lower than that
in Japanese (34.0%) [36,37], but much greater than that
of whites (8.0%) [5], Hispanic Americans (13.0%-16.0%)
[6,38] or Tunisian (13.0%) [39].The frequency of ApoA5
c.553G > T allele in this study is extremely low, and is in
agreement with that of two previous studies in Chinese
(3.97%) [40] and Chinese Taiwanese (4.2-7.2%) [41,42].
The ApoA5 c.553 T allele has been reported to be absent
in Caucasians [43]. The ApoA5 c.553TT homozygous
was similarly detected in our study population in agree-
ment with a previous study [40].
To the best of our knowledge, this study is the first to
determine that different haplotypes of APOA5 gene
modulate the systolic, diastolic blood pressure and lipid
levels in AHT patients. Thus, our data show markedly
higher systolic and diastolic blood pressure in subjectswith the APOA5 H2 and APOA5 H4 haplotypes, which
may explain the higher risk of coronary heart disease as-
sociated with the 56G and -1131C alleles [31,44].
In our study, both the APOA5 H2 and APOA5 H4
haplotypes were significantly associated with increase in
systolic blood pressure. In addition the H4 haplotype
was associated with higher DBP and TG levels. In con-
trast the H1 haplotype showed significant association
with lower SBP, DBP and total plasma TG. These results
suggest that each of these haplotypes may be associated
with different mechanisms that enhance the plasma lipid
levels and the risk of atherogenesis.
All these data suggested the importance of APOA5 in
the regulation of plasma triglyceride concentrations. Fur-
thermore, pair wise linkage disequilibrium comparison
performed in this study between APOA5 -1131 T < C
and APOA5 56C > G demonstrated that they are linked,
suggesting cooperation mechanisms for the associations
with plasma lipoproteins and related traits. Metabolic
syndrome (MetS) is a cluster of disorders which includes
visceral obesity, dyslipidaemia, hyperglycaemia, and
hypertension [45]. The association of APOA5 polymor-
phisms with increased risk of metabolic syndrome was
showed in several studies [46]. The APOA5 gene plays
an important role in regulating triglyceride levels. This
regulation may contribute to the association between
APOA5 and hypertension showed in this paper, but we
cannot exclude other mechanisms.
Our study has same limitations; waist conference
wasn’t measured to assess central obesity. In addition,
the APOA5 -1131 T > C and c.553G > T polymorphisms
were not in Hardy-Weinberg equilibrium.
In summary, we demonstrated that common variants
of APOA5 gene are associated with AHT and contribute
to the variation in human plasma TG. Therefore, APOA5
variant was a significant predictor for high triglyceride
risk and the APOA5 haplotypes affected dyslipidemia
appreciably among the Moroccan population.
Conclusion
In conclusion, we demonstrate for the first time that
APOA5 polymorphisms and haplotypes have a strong
Table 5 Association between APOA5 haplotypes and clinical and biochemical parameters
Haplotype H1 (TCG) Haplotype H2 (CCG) Haplotype H3 (TGG) Haplotype H4 (CGG)
Present Not
present
P value Present Not
present
P value Present Not
present
P value Present Not
present
P value
Age (years) 55.10 ± 12.36 57.52 ± 14.00 0.2276 56.97 ± 13.12 55.33 ± 12.62 0.4976 57.03 ± 14.38 55.33 ± 12.46 0.4865 57.50 ± 12.69 55.25 ± 12.66 0.3458
Sbp (mmgHg) 134.79 ± 19.84 155.00 ± 21.55 <0.0001** 152.55 ± 17.19 136.46 ± 21.33 <0.0001** 139.10 ± 21.19 138.11 ± 21.56 0.7795 157.56 ± 21.21 135.75 ± 20.27 <0.0001**
Dbp (mmgHg) 81.03 ± 10.41 86.48 ± 9.88 0.001** 86.35 ± 8.47 81.41 ± 10.62 0.0132* 81.40 ± 16.88 82.02 ± 9.52 0.7606 87.88 ± 8.59 81.20 ± 10.50 0.0006**
BMI (kg/m2) 26.85 ± 4.30 27.64 ± 4.90 0.2596 26.50 ± 4.67 27.04 ± 4.38 0.5181 27.11 ± 4.88 26.97 ± 4.36 0.8684 28.12 ± 5.56 26.83 ± 4.23 0.1195
TG (g/L) 1.24 ± 0.65 1.81 ± 0.92 <0.0001** 1.38 ± 0.69 1.33 ± 0.74 0.497 1.61 ± 1.00 1.31 ± 0.69 0.1055 1.99 ± 0.98 1.25 ± 0.65 <0.0001**
LDL(g/L) 1.23 ± 0.37 1.36 ± 0.47 0.0402* 1.42 ± 0.46 1.23 ± 0.38 0.0107* 1.24 ± 0.43 1.25 ± 0.39 0.8132 1.36 ± 0.45 1.24 ± 0.38 0.0883
HDL(g/L) 0.51 ± 0.16 0.45 ± 0.10 0.0061* 0.48 ± 0.10 0.50 ± 0.16 0.4389 0.47 ± 0.14 0.51 ± 0.16 0.2057 0.47 ± 0.12 0.51 ± 0.16 0.1585
Gly (g/L) 1.07 ± 0.46 1.12 ± 0.39 0.2406 1.16 ± 0.49 1.07 ± 0.44 0.1619 0.99 ± 0.21 1.09 ± 0.47 0.6938 1.08 ± 0.33 1.08 ± 0.46 0.5571
TC (g/L) 1.98 ± 0.41 2.15 ± 0.54 0.0122* 2.15 ± 0.53 1.99 ± 0.42 0.0604 2.00 ± 0.48 2.01 ± 0.43 0.8825 2.18 ± 0.54 1.98 ± 0.42 0.0162*
*P values not significant after Bonferroni correction.
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http://www.lipidworld.com/content/13/1/60influence on systolic and diastolic blood pressures and
triglyceride levels in Moroccan patients with AHT. Our
results showed that APOA5 56C > G and -1131 T > C
polymorphisms play a major role in elevated risk of de-
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